EBMT发布造血干细胞移植与细胞疗法支持性护理整合指南
The role of palliative and supportive care in haematopoietic cell transplantation and cellular therapy. Recommendations from the EBMT practice harmonisation and guidelines committee
EBMT发布《造血干细胞移植与细胞疗法中支持性护理整合指南》,强调全病程早期介入以改善症状控制和患者生活质量。
该指南为造血干细胞移植和细胞疗法中整合支持性护理提供了结构化框架,强调早期干预和跨学科合作,对提升患者症状管理及心理福祉具有直接指导意义。
Abstract
Haematopoietic cell transplantation (HCT) and cellular therapies (CT), including chimeric antigen receptor (CAR) T-cell therapy, offer curative potential for patients with haematologic malignancies but are associated with substantial physical, psychological, social and existential burden. Despite growing evidence that early integration of palliative and supportive care improves quality of life (QoL), symptom control, communication, and decision-making, its implementation remains heterogeneous and often delayed. This EBMT Practice Harmonisation and Guidelines paper was developed using a structured expert-consensus process. An international multidisciplinary panel of clinicians with expertise in adult and paediatric HCT, CT and palliative care conducted targeted literature reviews and discussions to generate pragmatic, non-graded recommendations. Recommendations address key domains across the HCT and CT continuum, including symptom management, psychological distress, graft-versus-host disease, relapse, end-of-life care, advance care planning, caregiver support, health inequities, and healthcare professional factors. Evidence supports early, integrated palliative care to reduce symptom burden, improve QoL, and facilitate complex decision-making. Practical referral triggers, incorporation of patient-reported outcomes, and parallel planning are proposed to promote timely and equitable access. Palliative and supportive care should be systematically integrated throughout HCT and CT. These EBMT recommendations provide a framework to support holistic, person-centred care and harmonise clinical practice.
Questions asked/issues to be addressed
-
What is the role of palliative care and symptom management in haematopoietic cell transplantation (HCT) and cellular therapy (CT)?
-
What evidence supports early integration of palliative care in relapse and graft-versus-host disease?
-
What evidence supports advance care planning in improving symptom burden, quality of life, communication, and complex, preference-sensitive decision-making in HCT and CAR T-cell patients?
-
Why should advance care planning be integrated early into HCT-CT pathways?
-
Which practical recommendations and referral triggers can standardise timely and equitable access to palliative and supportive care across the HCT and CT continuum?
-
How can multidisciplinary teams address psychological distress, caregiver needs, health inequalities, and healthcare professionals’ attitudes and competencies to deliver holistic, person-centred care in HCT and CT settings?
Current state of the art
Haematopoietic cell transplantation (HCT) and, more recently, cellular therapies (CT), including chimeric antigen receptor (CAR) T-cell therapy, represent established and potentially curative treatments for a wide range of haematological malignancies and non-malignant disorders [1]. However, they are associated with a substantial physical, psychological, social and existential burden for patients and families [2, 3] related to intensive conditioning, prolonged hospitalisation, treatment-related toxicities and complications, and unpredictable clinical deterioration [4, 5]. Within this context, transitions along the curative to palliative continuum are often non-linear and, in some patients - particularly those experiencing treatment failure or severe complications - may occur abruptly, leaving limited time for end-of-life (EoL) planning. Despite this, opportunities to integrate palliative and supportive care (PSC) remain frequently missed [6, 7], partly due to uncertainty regarding the role of palliative care (PC). This may result in fragmented care, unrealistic expectations, and poor communication [6] rather than care aligned with patient values and quality of life (QoL) [8, 9]. In contrast, growing evidence shows that early integrated PSC improves symptom control, psychological well-being, decision-making, and patient and caregiver satisfaction in HCT and CT [4, 10].
Palliative care, as defined by the World Health Organization (WHO), aims to improve quality of life for patients and families facing serious illness, through the prevention and relief of suffering, including physical, psychosocial and spiritual needs [11]. This definition has been criticised for its traditional focus on life-threatening conditions [12]. No longer reserved for EoL, PC in HCT and CT is increasingly recognised as integral to the entire treatment course, from early treatment discussions to survivorship or death [13, 14]. Delivery of PSC requires a multidisciplinary approach, involving specialist PC teams alongside HCT and CT clinicians [9, 15], and, where appropriate, primary and community services to ensure continuity of care.
In this paper, PSC refers to the prevention and management of treatment-related adverse effects across the disease continuum [16], with PC considered a core component of supportive care.
This EBMT Practice Harmonisation and Guidelines paper examines the role of PSC in HCT and CT and provides pragmatic, evidence-informed, non-graded recommendations, including clinically relevant referral triggers, to support timely integration and promote holistic, patient-centred care.
Methodology
This paper presents an expert-consensus guideline in accordance with the methodology of the EBMT practice harmonisation and guidelines committee [17, 18]. An international panel of nurses and physicians with expertise in paediatric or adult HCT, CT, and palliative care contributed to the recommendations. Following initial scoping searches, the panel defined key thematic areas, including symptom management, graft-versus-host disease (GvHD), relapse, advance care planning, health inequalities, caregiver support and healthcare professional (HCP) attitudes and competencies. Targeted literature searches were conducted by subtopic working groups.
The expert group met six times online before meeting in-person during a two-day consensus workshop in September 2025. Subgroups also met individually to review the evidence. A preliminary draft informed the discussion and the development of consensus-based recommendations (Tables 1–7). The available evidence was largely limited to descriptive studies, with few randomised trials; therefore, the recommendations were not graded. Where HCT- and CT-specific data were lacking, relevant evidence from oncology and PC literature was considered. The draft manuscript was reviewed by patient representatives and external experts to ensure clinical relevance and applicability.
EBMT recommendations
Role of palliative care and symptom management in HCT and CT
Because HCT and CT are potentially curative or life-prolonging, the role of PSC in transplant-related symptom management remains inconsistently defined and implemented [19]. Patients frequently experience profound physical, psychological, and existential burden that impairs QoL [20]. Integrated PSC can address persistent symptoms in survivors [21, 22], thus facilitating comprehensive symptom management and patient-centred decision-making across the HCT and CT trajectory [23].
The intensity and prognostic uncertainty of HCT and CT place patients at high risk of psychological distress, including anxiety, depression, post-traumatic stress, and existential suffering, which may persist beyond the acute treatment phase. Evidence supports PC integration to mitigate these effects. A randomised trial in HCT patients demonstrated reduced depression and PTSD symptoms with PC [20], with early improvements in symptom burden and anxiety contributing to longer-term benefits. Patients, particularly those facing refractory disease or relapse, may also experience substantial existential and spiritual distress [24], highlighting the importance of holistic palliative interventions addressing psychological, social, and spiritual domains.
HCT and CT are associated with a substantial physical symptom burden, typically peaking early post-transplant, including pain, mucositis, fatigue, gastrointestinal disturbances, and sleep disruption [25,26,27], leading to functional impairment and reduced QoL.
CT poses additional challenges due to unpredictable, potentially life-threatening toxicities, including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome [17], often requiring intensive care and placing additional demands on PC services.
Pharmacological management in HCT and CT should reduce symptom burden while minimising adverse effects, including dependency or addiction [28, 29]. Although many treatment-related symptoms improve over time, others, such as fatigue and gastrointestinal disturbances, may persist [6, 20]. Integrated PC improves the control of common symptoms, including pain, nausea, and diarrhoea [26, 30], while supporting the safe use of analgesics with clear treatment goals to mitigate risks associated with prolonged opioid therapy [31].
Symptom burden typically worsens with disease relapse and towards the EoL [32, 33]. During these phases, patients experience a complex interplay of physical, psychological, and existential symptoms, requiring comprehensive and multidisciplinary management. PC integration has been consistently associated with improved symptom recognition, more targeted and timely interventions, and better coping, reducing overall burden [25,26,27].
Despite this, patients with haematological malignancies are less likely to access PC and more likely to die in hospital following escalating interventions [34]. A shift from prognosis-based to needs-based referral may improve care quality, facilitate earlier integration, and better align treatment with patient goals.
Randomised trials showed that early inpatient PC mitigates QoL decline after HCT, with sustained improvements in QoL, mood, coping and well-being up to six months post-transplant [6, 25, 30]. Importantly, patients with the poorest baseline QoL and highest symptom burden derive the greatest benefit [30], supporting routine assessment of QoL and symptom burden to identify patients at higher risk and facilitate timely, targeted PC interventions.
In paediatric HCT, QoL is similarly compromised, particularly in advanced disease and towards the EoL, where escalating physical and psychological distress impairs functional status and overall well-being [32, 33]. Parents and caregivers consistently emphasise that early PC integration may improve QoL by addressing symptom burden and psychosocial needs [9], and by supporting communication and decision-making throughout the disease trajectory. Recommendations are summarised in Table 1.
Relapse after HCT and CT
Prognosis after relapse following HCT and CT is generally poor, with limited therapeutic options [35, 36]. Relapse is associated with high symptom burden, psychological distress, and reduced curative potential, especially when occurring early [37]. Treatment is often individualised and may include further disease-directed therapies, such as immunotherapeutic approaches, alongside PC. An exception is paediatric patients with relapsed B-ALL after allogeneic HCT, who may have improved outcomes due to availability of effective CT. However, treatment in the relapse setting is associated with increased toxicity and symptom burden, further impacting QoL [38]. Recommendations are summarised in Table 2.
Graft-versus-host disease
Graft-versus-host disease is a common and potentially life-threatening complication of allogeneic HCT. Severe GvHD may shift treatment goals from curative intent towards PC and is associated with significant physical and psychological burden. A literature review [39] reported that up to one-third of patients experience impaired QoL, with disease severity as the main determinant.
Conventional clinician-assessed grading systems (NIH consensus criteria) [40] do not fully capture the functional impact of GvHD, including QoL and symptom burden. Patient-reported outcomes (PROs) better reflect patient-experienced morbidity and psychosocial distress. While some PROs are validated for chronic GVHD (cGVHD), tools for acute GVHD remain limited [41].
Graft failure following allogeneic transplantation requires careful immunosuppression management to balance treatment-related toxicity with future treatment options, including retransplantation. In advanced disease stages or near the EoL, immunosuppression de-escalation or withdrawal may be considered to control symptoms and GvHD-related complications, alongside ethical considerations in decision-making [42].
Polypharmacy is common in moderate to severe cGVHD with increased use of medications for pain, anxiety, and depression compared with patients without or with resolved cGvHD [43]. This underscores the importance of integrated PC in optimising symptom management, rationalising treatment, and supporting patients and families. Recommendations are summarised in Table 3.
Advance care planning, goals of care, communication
Advance care planning (ACP) is defined as ‘a process that supports adults at any age or stage of health in understanding and sharing their personal values, life goals, and preferences regarding future medical care’ [44, 45]. A Delphi study convened to define ACP priorities found that a lack of consensus regarding the definition of ACP hindered progress. Thus, they elaborated ‘advance care planning as ensuring that people receive medical care consistent with their values, goals and preferences during serious and chronic illness’ and ‘this process may include choosing and preparing another trusted person or persons to make medical decisions in the event the person can no longer make his or her own decisions’. Despite its recognised importance, evidence on ACP in HCT and CT remains limited.
Patients with haematological malignancies are less likely to receive PC and typically access services later than those with solid tumours [46], contributing to more aggressive and lower-quality EoL care [46]. Although patients value shared decision-making and prognostic information, discussions in HCT and CT are often delayed [47, 48]. Prognostic uncertainty in HCT and CT complicates ACP, but open discussions may also foster hope [49].
ACP is often misperceived as synonymous with EoL care, contributing to delayed introduction [47, 50]. Barriers include prognostic uncertainty, resulting in overtreatment [46], and failure to address cultural, spiritual and religious preferences [51]. A systematic review identified key factors influencing ACP engagement, including limited awareness, financial constraints, faith, and family involvement [52].
Early PC integration in CAR-T pathways is feasible and beneficial, even in uncertain and potentially curative settings [53, 54]. PC supports symptom management, communication, ACP and coordination of care transitions, particularly for patients who don’t proceed to CAR-T or who relapse, where delayed referral reduces benefit [55].
In paediatric oncology, PC improves QoL, symptom control, and family support, while reducing hospitalisations [56]. Early ACP and PC conversations align care with patient goals, support families and improve bereavement outcomes [57]. Serious Illness Conversations, although distinct from ACP [8], reduce aggressive treatment at the EoL, increase specialist PC referrals, and are associated with more deaths at home or in palliative facilities rather than in ICUs [14, 58, 59].
ACP should adopt a parallel planning approach - hoping for the best and preparing for the worst [49, 60] – underpinned by honest, empathetic communication and trust [61]. Clear documentation and regular review are essential, given evolving clinical trajectories and patient preferences. Recommendations are summarised in Table 4.
Health inequalities and access to palliative care in HCT and CT
Palliative and supportive care improve QoL, symptom management, and emotional coping in patients undergoing HCT and CT, but access remains unequal. Disparities related to race, socioeconomic status and other social determinants are associated with reduced HCT use, poorer outcomes, and limited access to PC [26, 62]. In contrast, patients from minoritised ethnic groups, those with lower baseline QoL, and higher symptom burden may derive greater benefit from early PC integration [30]. Although integrated supportive care improves outcomes, variations in service availability and access continue to drive inequities in patient experience [25, 26].
Socioeconomic and geopolitical disparities globally hinder access to PC, especially in resource-limited settings with workforce shortages, inadequate infrastructure, and limited health system prioritisation. In such contexts, unmet PC needs in haematology are further exacerbated by limited awareness of services and lack of transfusion support [63]. Addressing these inequities requires international collaboration, policy reform, and investment in education and infrastructure [64].
Underrepresentation of racial and ethnic minority groups in clinical trials limits equitable access to supportive care interventions and reduces generalisability to diverse populations. The use of single-language patient information and educational materials further restricts accessibility, highlighting the need for cultural adaptation and translation to ensure inclusivity [62].
Equitable access to PC requires community engagement in healthcare decision-making, research, and service implementation. Incorporating cultural values and preferences enhances PC service acceptability, reduces stigma, and improves engagement. To meet the growing and diverse needs of patients with life-limiting illnesses, health systems must expand capacity and prioritise PC. Integration into primary and community-based services offers a sustainable and equitable approach to improving access and advancing universal health coverage [62].
Finally, health technology and telemedicine offer opportunities to mitigate disparities in access to PC by enabling self-administration and reducing barriers to care. However, their effectiveness may be limited by training needs and digital literacy, particularly in underserved populations [62]. Telehealth-delivered early PC provides improvements in QoL and symptom burden comparable to in-person care, supporting its role in improving access as a strategy to effectively mitigate disparities [65]. Emerging approaches, including digital health technology and virtual reality interventions, may further support the needs of patients undergoing HCT and CT [66]. Recommendations are summarised in Table 5.
Supporting caregivers in HCT and CT
The HCT journey presents significant challenges for informal caregivers, impacting their physical, psychological, and financial well-being [67, 68]. Caregivers frequently experience high levels of stress and emotional burden [69], often accompanied by isolation and loss of identity [15, 70]. These needs are significant and persistent, emphasising the importance of early and continuous support [69]. In paediatric settings, parents face additional challenges including feelings of inadequacy towards healthy siblings, due to their focus on the ill child [71]. In EoL decision-making, they may adopt a survival-oriented approach and later experience doubts regarding prior decisions and their child’s suffering [72]. Early integration of PC provides comprehensive support to patients and families [9]. Caregiver loneliness is associated with increased psychological distress, including anxiety and depression [13], while financial burden – often due to out-of-pocket costs such as transportation, accommodation and food – remains a major concern [67]. Comprehensive education programmes, structured care planning and open, compassionate communication are essential to prepare caregivers for care transitions [9, 10] and shared decision-making, improving resilience [15, 73] and reducing distress [68]. Recommendations are summarised in Table 6.
Attitudes of HCT, CT and palliative healthcare professionals
Studies show that HCP involved in HCT and CT generally hold positive attitudes towards PC [4, 74], but its integration remains inconsistent [4, 75]. A survey among PC physicians identified key barriers, including misperceptions of PC and lack of a shared model of care, despite strong interest in earlier integration [76]. In paediatric settings, most HCT professionals report access to specialised PC services, although referral rates remain low [75]. Overall, variability in practice persists despite broadly supportive attitudes across multidisciplinary teams [77, 78].
Healthcare professionals in HCT and CT face challenges in integrating PC, affecting care quality and team collaboration. They may experience moral distress and emotional burden when curative treatments fail or when transitioning to PC [4, 27, 76,77,78]. Early PC integration is widely supported but often delayed due to prognostic uncertainty, cultural factors, a cure-oriented approach and lack of clear referral triggers [4, 27, 74, 79,80,81,82]. The term “palliative care” is often associated with EoL, fear, and loss of hope, negatively impacting referral decisions [4, 78, 80, 81]. In addition, transplant and haematology professionals may feel ownership of patient care, leading to reluctance in involving PC teams [4, 76,77,78]. Interdisciplinary teamwork improves workflow, care quality, and staff engagement, and effective collaboration across transplant, nutrition, nursing, and PC teams is essential [80, 83, 84]. However, integration is often limited by lack of protocols, limited access to PC services, and insufficient training in palliative approaches [27, 74, 79, 80, 82, 84]. Haematologic malignancies and paediatric oncology require tailored palliative approaches due to unique disease trajectories and treatment paradigms, which demands understanding from PC teams to become effective partners [76, 81, 82]. Table 7 summarises recommendations.
Implementation considerations
Implementation of integrated PSC should be adapted to local resources, professional scopes of practice and healthcare systems. Basic palliative and supportive care principles, including symptom assessment, communication and identification of unmet needs, should be embedded within HCT and CT teams, while specialist PSC input should be prioritised for patients with complex or refractory needs. Referral pathways should clearly define responsibilities for screening, referral initiation, documentation, follow-up and re-engagement when PSC is initially declined.
Centres should assess institutional readiness, including access to specialist PSC, staff training, multidisciplinary collaboration and mechanisms for continuity across inpatient, outpatient and community settings. Potential barriers include limited specialist PSC availability, insufficient staff training, unclear professional responsibilities, fragmented care pathways and variable perceptions of PC among healthcare professionals and patients. Mitigation strategies may include locally adapted referral pathways, staff education, shared-care models, telemedicine and strengthened links with community services. Quality improvement should include monitoring of referral rates, timeliness of access, uptake of PSC, documentation of care preferences and patient-reported outcomes. Table 8 provides a pragmatic framework that can be adapted to local organisational and resource contexts.
Conclusion – unanswered questions and further research to do in the field
This EBMT Practice Harmonisation and Guidelines paper provides consensus-based recommendations on the role of PSC in HCT and CT, supporting HCPs in delivering holistic, patient-centred care.
Our recommendations emphasise symptom management and QoL, rather than equating PC with EoL care. This requires a cultural and organisational shift, including education of clinicians, patients, and caregivers to reframe PC as an integral component of care throughout the patient pathway.
Early integrated PC reduces symptom burden, psychological distress, and improves QoL. Proactive ACP and continuity of care support patient-centred decision-making and smoother transitions across treatment phases. HCT and CT specialists should integrate PC early and maintain it throughout the care pathway, with a parallel planning approach. However, variability in organisation and reimbursement across countries may limit access. To promote equity, accreditation programmes such as JACIE should include standards for integrated PSC. Key referral triggers are summarised in Table 9 to guide clinical practice and support service evaluation.
Further research on PSC in HCT and CT is essential to ensure high-quality care. Priority areas include evaluating key interventions such as parallel planning, ACP, PROs, structured PC training, validated referral triggers, telemedicine models, and coordinated care pathways between HCT/CT and PC teams. Future research should incorporate patient and caregiver perspectives, especially from underserved populations, to inform the design, delivery, and evaluation of PSC interventions.
References
Passweg JR, Baldomero H, Chabannon C, Basak GW, Corbacioglu S, Duarte R, et al. The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T’s come into focus. Bone Marrow Transpl. 2020;55:1604–13.
El-Jawahri AR, Traeger LN, Kuzmuk K, Eusebio JR, Vandusen HB, Shin JA, et al. Quality of life and mood of patients and family caregivers during hospitalization for hematopoietic stem cell transplantation. Cancer. 2015;121:951–9.
Buchbinder D, Khera N. Psychosocial and financial issues after hematopoietic cell transplantation. Hematology. 2021;2021:570–7.
El-Jawahri A, LeBlanc TW, Burns LJ, Denzen E, Meyer C, Mau LW, et al. What do transplant physicians think about palliative care? A national survey study. Cancer. 2018;124:4556–66.
Gray TF, Do KM, Amonoo HL, Sullivan L, Kelkar AH, Pirl WF, et al. Family caregiver experiences in the inpatient and outpatient reduced-intensity conditioning allogeneic hematopoietic cell transplantation settings: a qualitative study. Transpl Cell Ther. 2024;30:610.e1–610.e16.
Mitchell SA. Palliative care during and following allogeneic hematopoietic stem cell transplantation. Curr Opin Support Palliat Care. 2018;12:58–64.
Robbins-Welty GA, Webb JA, Shalev D, El-Jawahri A, Jackson V, Mitchell C, et al. Advancing palliative care integration in hematology: building upon existing evidence. Curr Treat Options Oncol. 2023;24:542–64.
Bernacki R, Hutchings M, Vick J, Smith G, Paladino J, Lipsitz S, et al. Development of the Serious Illness Care Program: a randomised controlled trial of a palliative care communication intervention. BMJ Open. 2015;5:e009032.
Levine DR, Epperly R, Collins G, Talleur AC, Mandrell B, Pritchard M, et al. Integration of palliative care in hematopoietic cell transplant: pediatric patient and parent needs and attitudes. J Pain Symptom Manag. 2023;66:248–57.
Gray TF, Revette AC, Nava-Coulter B, Gould K, Close S, Sullivan LM, et al. Caregiver experiences managing information prior to hematopoietic stem cell transplantation and after transition to home: a qualitative study. Support Care Cancer. 2025;33:402.
Sepúlveda C, Marlin A, Yoshida T, Ullrich A. Palliative care: the World Health Organization’s global perspective. J Pain Symptom Manag. 2002;24:91–96.
Murray SA, Kendall M, Mitchell G, Moine S, Amblas-Novellas J, Boyd K. Palliative care from diagnosis to death. BMJ. 2017;356:j878.
Lee LJ, Son H, Wallen GR, Flynn S, Cox R, Yang L, et al. Symptom clusters in family caregivers of hematopoietic stem cell transplantation recipients: loneliness as a risk factor. Transpl Cell Ther. 2023;29:50.e1–50.e8.
Korsos V, Ahmed S, Heslip S, Shamy A, Kaedbey R, Greenfeld SM, et al. The serious illness conversation guide is meaningful to patients with hematologic malignancies and impacts death in acute care. Blood. 2024;144:3670.
Tierney DK, Passaglia J, Jenkins P. Palliative care of hematopoietic cell transplant recipients and families. Semin Oncol Nurs. 2014;30:253–61.
Multinational Association of Supportive Care in Cancer. What is supportive care?, 2025, from https://mascc.org/what-is-supportive-care [accessed Sept 2025].
Yakoub-Agha I, Chabannon C, Bader P, Basak GW, Bonig H, Ciceri F, et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). haematologica. 2019;105:297.
Yakoub-Agha I, Greco R, Onida F, De La Cámara R, Ciceri F, Corbacioglu S, et al. Practice harmonization workshops of EBMT: an expert-based approach to generate practical and contemporary guidelines within the arena of hematopoietic cell transplantation and cellular therapy. Bone Marrow Transpl. 2023;58:696–700.
Simon ST, Pralong A, Hallek M, Scheid C, Holtick U, Herling M. What is known about palliative care in adult patients with allogeneic stem cell transplantation (allo-SCT)?. Ann Hematol. 2021;100:1377–89.
El-Jawahri A, Traeger L, Greer JA, VanDusen H, Fishman SR, LeBlanc TW, et al. Effect of inpatient palliative care during hematopoietic stem-cell transplant on psychological distress 6 months after transplant: results of a randomized clinical trial. J Clin Oncol. 2017;35:3714–21.
Pidala J, Anasetti C, Jim H. Quality of life after allogeneic hematopoietic cell transplantation. Blood. 2009;114:7–19.
El-Jawahri A, Webb JA, Hannon B, Zimmermann C. Integrating palliative care and hematologic malignancies: bridging the gaps for our patients and their caregivers. Am Soc Clin Oncol Educ Book. 2024;44:e432196.
Barata A, Abrams HR, Meyer C, Mau L-W, Mattila D, Burns LJ, et al. What do patients think about palliative care? A national survey of hematopoietic stem cell transplant recipients. Blood Adv. 2023;7:2032–41.
Zheng L-Y, Yuan H, Zhou Z-J, Guan B-X, Zhang P, Zhang X-Y. The role of spirituality in patients undergoing hematopoietic stem cell transplantation: a systematic mixed studies review. J Gen Intern Med. 2020;35:2146–61.
El-Jawahri A, LeBlanc T, VanDusen H, Traeger L, Greer JA, Pirl WF, et al. Effect of inpatient palliative care on quality of life 2 weeks after hematopoietic stem cell transplantation: a randomized clinical trial. JAMA. 2016;316:2094–103. https://doi.org/10.1001/jama.2016.16786.
Nelson AM, Johnson PC, Kavanaugh AR, Jackson VA, Jagielo AD, Fenech AL, et al. Palliative care for patients undergoing stem cell transplant: intervention components and supportive care measures. Bone Marrow Transpl. 2021;56:1971–7.
Pralong A, Simon ST, Holtick U, Reimer A, Schoerger B, Kaur S, et al. A cross-sectional survey on health care professionals’ approaches, challenges, and support needs when addressing life threat with recipients of an allogeneic hematopoietic stem cell transplantation and with their relatives. Ann Hematol. 2025;104:741–51.
Guideline NG193 NICE. Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain. In: Methods.2021 Apr;10. (niceng193er6_bm1.pdf).
Glare P, Aubrey K, Gulati A, Lee YC, Moryl N, Overton S. Pharmacologic management of persistent pain in cancer survivors. Drugs. 2022;82:275–91.
Newcomb R, Amonoo HL, Kavanaugh AR, Wharton KC, Rowland M, Fausto J, et al. Factors associated with early quality-of-life response to palliative care during hematopoietic cell transplantation. Blood Adv. 2025;9:2033–43.
Pederson C, & Parran L. Opioid tapering in hematopoietic progenitor cell transplant recipients. OncologyNursing Forum, 2000,27:1371–1380.
Snaman JM, Kaye EC, Baker JN, Wolfe J. Pediatric palliative oncology: the state of the science and art of caring for children with cancer. Curr Opin Pediatr. 2018;30:40–48.
Humphrey L, Kang TI. Palliative care in pediatric patients with hematologic malignancies. Hematol Am Soc Hematol Educ Program. 2015;2015:490–5.
Manitta VJ, Philip JA, Cole-Sinclair MF. Palliative care and the hemato-oncological patient: can we live together? A review of the literature. J Palliat Med. 2010;13:1021–5.
Thanarajasingam G, Kim HT, Cutler C, Ho VT, Koreth J, Alyea EP, et al. Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2013;19:1713–8.
Zurko J, Ramdial J, Shadman M, Ahmed S, Szabo A, Iovino L, et al. Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma. Haematologica. 2022;108:98.
Gooptu M, Murdock HM, Soiffer RJ. How I treat AML relapse after allogeneic HSCT. Blood. 2025;145:2128–37.
Kuhlen M, Willasch AM, Dalle JH, Wachowiak J, Yaniv I, Ifversen M, et al. Outcome of relapse after allogeneic HSCT in children with ALL enrolled in the ALL-SCT 2003/2007 trial. Br J Haematol. 2018;180:82–89.
Wenzel F, Pralong A, Holtick U, Scheid C, Herling M, Simon ST. Burden and needs of patients with severe GvHD from the supportive and palliative care perspective—a literature review. Cancers. 2021;13:2697.
Lee SJ. Classification systems for chronic graft-versus-host disease. Blood J Am Soc Hematol. 2017;129:30–37.
Kilgour JM, Wali G, Gibbons E, Scherwath A, Badiella AB, Peniket A, et al. Systematic review of patient-reported outcome measures in graft-versus-host disease. Biol Blood Marrow Transpl. 2020;26:e113–e127.
Birchler KM, Hertler C, Pfrunder T, Blum D, Schettle M. Immunosuppressant management in palliative care: a systematic review. BMC Palliat Care. 2025;24:187.
Lee SJ, Onstad L, Chow EJ, Shaw BE, Jim HS, Syrjala KL, et al. Patient-reported outcomes and health status associated with chronic graft-versus-host disease. Haematologica. 2018;103:1535.
Rietjens JA, Sudore RL, Connolly M, van Delden JJ, Drickamer MA, Droger M, et al. Definition and recommendations for advance care planning: an international consensus supported by the European Association for Palliative Care. Lancet Oncol. 2017;18:e543–51.
Sudore RL, Lum HD, You JJ, Hanson LC, Meier DE, Pantilat SZ, et al. Defining advance care planning for adults: a consensus definition from a multidisciplinary Delphi panel. J Pain Symptom Manag. 2017;53:821–32.e1.
Wedding U. Palliative care of patients with haematological malignancies: strategies to overcome difficulties via integrated care. Lancet Healthy Longev. 2021;2:e746–53.
Gemmell R, Halley A, Stevens A-M, Allam A, Perkins M, Ethell M, et al. Palliative care for patients around the time of haematopoietic stem cell transplant: a qualitative study of patients’ perceptions and experiences of unmet need and attitudes towards palliative care involvement. Support Care Cancer. 2022;30:2253–61.
Lymphoma Coalition. Global Patient Survey on Lymphomas & CLL. 2024.2024. https://lymphomacoalition.org/global-patient-survey/ [accessed Sept 2025].
Shaulov A, Aviv A, Alcalde J, Zimmermann C. Early integration of palliative care for patients with haematological malignancies. Br J Haematol. 2022;199:14–30.
Short AC, Kuroki M, Coombs LA. Palliative care referral in adult allogeneic hematopoietic stem cell transplants: an integrative literature review. Am J Hosp Palliat Med. 2024;42:962–70.
Liu Q, Li J, Wang L, Shan C, Wang L, Ye D, et al. Shared decision-making about autologous stem cell transplantation: a qualitative study of older patients and physicians. J Am Geriatr Soc. 2025;73:458–69.
Crooks J, Trotter S, Clarke G, Patient Public Involvement Consortium. How does ethnicity affect presence of advance care planning in care records for individuals with advanced disease? A mixed-methods systematic review. BMC Palliat Care. 2023;22:43.
Williams R, Droney J, Nicholson E, Arias C, Ellard R, Bradley N, et al. 1614P Integrated palliative care for patients referred for Chimeric Antigen Receptor T-cell (CAR-T) therapy: a service evaluation. Ann Oncol. 2023;34:S892–3.
Stenson CL, Vidrine J, Dewhurst F, Osborne W, Menne T, Stocker R. A qualitative service evaluation of patient and caregiver experiences of CAR-T therapy: Recommendations for service development and implications for palliative care teams. Palliat Med. 2023;37:215–20.
Johnson PC, Jacobson C, Yi A, Saucier A, Dhawale TM, Nelson A, et al. Healthcare utilization and end-of-life outcomes in patients receiving CAR T-cell therapy. J Natl Compr Cancer Netw. 2021;19:928–34.
Kaye EC, Weaver MS, DeWitt LH, Byers E, Stevens SE, Lukowski J, et al. The impact of specialty palliative care in pediatric oncology: a systematic review. J Pain Symptom Manag. 2021;61:1060–79.e2.
Cooper A, Dains JE. Advanced care planning and end-of-life outcomes in hematopoietic stem cell transplant patients. Am J Hosp Palliat Med. 2021;38:995–1003.
Myrhøj CB, Bernacki R, Bjerre-Bertelsen S, Jacobsen J, Klintman J, Jarden M, et al. Serious illness conversations and quality of end-of-life care in patients with hematological malignancies—a retrospective quality improvement study. Support Care Cancer. 2025;33:814.
Cappell K, Sundaram V, Park A, Shiraz P, Gupta R, Jenkins P, et al. Advance directive utilization is associated with less aggressive end-of-life care in patients undergoing allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2018;24:1035–40.
Sidgwick P, Fraser J, Fortune P-M, McCulloch R. Parallel planning and the paediatric critical care patient. Arch Dis Child. 2019;104:994–7.
Hayek MF, Hammad BM, Eqtait FA, Ayed A, Salameh B, Said NB, et al. Enhancing oncology patient care: nurses’ knowledge, attitudes, and perceived benefits of early palliative integration-a cross-sectional study. BMC Palliat Care. 2025;24:7.
Trunk AD, Guo M, Budvytyte L, Islam NS, Khera N, Hamilton BK, et al. Hematopoietic stem-cell transplantation: exploring the latest advances and gaps in disparities, psychosocial and symptom management interventions, and chronic graft-versus-host disease care. Am Soc Clin Oncol Educ Book. 2024;44:e432186.
Wang W, Roeland E, LeBlanc T, El-Jawahri A. Palliative care for the hematopoietic cell transplant and cellular therapy clinician.In: Finn, L., Roche Green, A.R. (eds) Supportive Care Strategies. Advances and Controversies in Hematopoietic Transplantation and Cell Therapy. Springer, Cham. 2020. p. 5–21.
Peeler A, Afolabi OA, Sleeman KE, El Akoum M, Gafer N, Hammerich A, et al. Confronting global inequities in palliative care. BMJ Glob Health. 2025;10:e017624.
Greer JA, Temel JS, El-Jawahri A, Rinaldi S, Kamdar M, Park ER, et al. Telehealth vs in-person early palliative care for patients with advanced lung cancer: a multisite randomized clinical trial. JAMA. 2024;332:1153–64.
Chow H, Hon J, Chua W, Chuan A. Effect of virtual reality therapy in reducing pain and anxiety for cancer-related medical procedures: a systematic narrative review. J Pain Symptom Manag. 2021;61:384–94.
Waters AR, Biddell CB, Killela M, Kasow KA, Page K, Wheeler SB, et al. Financial burden and recommended multilevel solutions among caregivers of pediatric hematopoietic stem cell transplant recipients. Pediatr Blood Cancer. 2023;70:e30700.
Yang X, Zeng Q, Tan S, Zhou H, Qiu X, Yan J. Psychosocial situation, burden, and unmet needs among informal caregivers prior to hematopoietic stem cell transplantation: a systematic review of quantitative and qualitative data. Support Care Cancer. 2025;33:119. https://doi.org/10.1007/s00520-024-09073-2.
Kisch AM, Bergkvist K, Alvariza A, Årestedt K, Winterling J. Family caregivers’ support needs during allo-HSCT—a longitudinal study. Support Care Cancer. 2021;29:3347–56.
Jacobs JM, Nelson AM, Traeger L, Waldman L, Nicholson S, Jagielo AD, et al. Enhanced coping and self-efficacy in caregivers of stem cell transplant recipients: identifying mechanisms of a multimodal psychosocial intervention. Cancer. 2020;126:5337–46.
Rinaldo C, Stenmarker M, Øra I, Pergert P. Living with the threat of losing a child: Parents’ experiences of the transplantation process with a severely ill child who received stem cells from a sibling. J Pediatr Nurs. 2024;77:e495–502.
Mekelenkamp H, Lankester AC, Bierings MB, Smiers FJ, de Vries MC, Kars MC. Parental experiences in end-of-life decision-making in allogeneic pediatric stem cell transplantation: “Have I been a good parent?”. Pediatr Blood Cancer. 2020;67:e28229.
Maleki M, Nayeri ND, Hamidieh AA, Pouraboli B, Mardani A. Harmony in hardship: Unveiling parental coping strategies with the challenges of child’s hematopoietic stem cell transplantation. J Pediatr Nurs. 2024;77:e202–10.
Di Lorenzo S, Mozzi L, Salmaso F, Silvagni C, Soffientini S, Valenti V, et al. A multicentre survey on the perception of palliative care among health professionals working in haematology. Support Care Cancer. 2024;32:253.
Mekelenkamp H, Schröder T, Trigoso E, Hutt D, Galimard J-E, Kozijn A, et al. Specialized pediatric palliative care services in pediatric hematopoietic stem cell transplant centers. Children. 2021;8:615.
Santivasi WL, Childs DS, Wu KL, Partain DK, Litzow MR, LeBlanc TW, et al. Perceptions of hematology among palliative care physicians: results of a nationwide survey. J Pain Symptom Manag. 2021;62:949–59.
Reimer A, Ley M, Schepers C, Pralong A, Schoerger B, Voltz R, et al. The life threat in hematopoietic allogeneic stem cell transplantation-an interview and focus group study on health care professionals’ perspectives. Ann Hematol. 2024;103:4251–9.
LeBlanc TW, El-Jawahri A. When and why should patients with hematologic malignancies see a palliative care specialist?. Hematol Am Soc Hematol Educ Program. 2015;2015:471–8.
Pitzer S, Kutschar P, Paal P, Mülleder P, Lorenzl S, Wosko P, et al. Barriers for adult patients to access palliative care in hospitals: a mixed methods systematic review. J Pain Symptom Manag. 2024;67:e16–e33.
Collins GS, Beaman H, Ho AM, Hermiston ML, Cohen HJ, Dzeng EW. Perceptions of specialty palliative care and its role in pediatric stem cell transplant: a multidisciplinary qualitative study. Pediatr Blood Cancer. 2022;69:e29424.
Parisio KN, Levy CD, Lewis AM, Schultz CL. Attitudes and practices of pediatric oncologists regarding palliative care consultation for pediatric oncology patients. J Pediatr Hematol Oncol. 2022;44:230–6.
Treml J, Schmidt V, Nagl M, Kersting A. Pre-loss grief and preparedness for death among caregivers of terminally ill cancer patients: a systematic review. Soc Sci Med. 2021;284:114240.
Hollasch M. Multidisciplinary Teamwork Yields Improvements in HSCT Workflow and Care. Oncology Nursing News. 2023.
Miller LJ, Halliday V, Snowden JA, Aithal GP, Lee J, Greenfield DM. Health professional attitudes and perceptions of prehabilitation and nutrition before haematopoietic cell transplantation. J Hum Nutr Dietetics. 2024;37:1007–21.
Acknowledgements
The authors would like to express sincere gratitude to Helene Schoemans and Andrea Linke for their insightful comments and suggestions, which greatly contributed to the refinement of this manuscript. This manuscript was written by human authors. During the preparation of this work, the authors used AI tools to enhance the clarity, conciseness, and grammatical accuracy of the text. Following this assistance, all content was carefully reviewed and edited by the authors, who take full responsibility for the final version of the manuscript.
Funding
The European Group for Blood and Bone Marrow Transplantation (EBMT) is a non-for-profit medical and scientific organisation. The EBMT performed administrative and legal management, as well as funding acquisition. No pharmaceutical company and no other funding source were involved in any way or had a role in the study design, data collection, data analysis, data interpretation, or writing of the report. No medical writer or editor was involved.
Author information
Authors and Affiliations
EBMT Nurses Group, Leiden, The Netherlands
Michelle Kenyon, Ozgun Gokmen Kaya, Elin Ofverberg & Hilda Mekelenkamp
Department of Haematology, King’s College Hospital NHS Foundation Trust, London, UK
Michelle Kenyon
Co-Chair of the Practice Harmonisation and Guidelines Committee, EBMT, Barcelona, Spain
Francesco Onida & Analisa Ruggeri
Hematology and BMT Centre, ASST Fatebenefratelli-Sacco, University of Milan, Milan, Italy
Francesco Onida
Haematology and BMT Unit, IRCCS San Raffaele Hospital, Milano, Italy
Andrea Assanelli, Raffaella Greco & Analisa Ruggeri
Department of Nursing, Autonomous University of Madrid, Madrid, Spain
Maria Aviles Martinez
Palliative Care Department, University of Nantes; Nantes University Hospital, Nantes, France
Kim Courbin
Graduate School of Health Sciences, Koç University, Istanbul, Turkey
Ozgun Gokmen Kaya
Pediatric Diseases Working Party, EBMT, Paris, France
Andrea Jarisch
Division of Paediatric Stem Cell Transplantation and Immunology, Goethe University Frankfurt, Department of Children and Adolescents, Frankfurt University Hospital, Frankfurt am Main, Germany
Andrea Jarisch
St. Anna Children’s Hospital, Stem Cell Transplantation Unit, Vienna, Austria
Jennifer Linder
Equality, Diversity & Inclusion Committee, EBMT, Barcelona, Spain
Silvia Montoto
Department of Haemato-oncology, St Bartholomew’s Hospital; Barts Health NHS Trust, London, UK
Silvia Montoto
The Queen Silvia Childrens Hospital, Department of Paediatric Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden
Elin Ofverberg
Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, UK
Jennifer Vidrine
Secretary of the Practice Harmonisation and Guidelines Committee, EBMT, Barcelona, Spain
Isabel Sánchez-Ortega
Chief Medical Officer EBMT, Executive Office, Barcelona, Spain
Isabel Sánchez-Ortega
Chair of the EBMT Practice Harmonisation and Guidelines Committee, EBMT, Barcelona, Spain
Ibrahim Yakoub-Agha
Lille University Hospital, Lille University, INSERM U1286, Infinite, Lille, France
Ibrahim Yakoub-Agha
Willem-Alexander Children’s Hospital, Department of Paediatrics, Leiden University Medical Center, Leiden, the Netherlands
Hilda Mekelenkamp
Authors
- Michelle Kenyon
- Francesco Onida
- Andrea Assanelli
- Maria Aviles Martinez
- Kim Courbin
- Ozgun Gokmen Kaya
- Raffaella Greco
- Andrea Jarisch
- Jennifer Linder
- Silvia Montoto
- Elin Ofverberg
- Jennifer Vidrine
- Analisa Ruggeri
- Isabel Sánchez-Ortega
- Ibrahim Yakoub-Agha
- Hilda Mekelenkamp
Contributions
MK and HM are the leaders of this workshop. They conceived and designed the manuscript topics. MK, HM, AA, MAM, KC, OGK, RG, AJ, JL, EO and JV participated in the workshop, contributed to the literature review, data interpretation, formulation of recommendations, and preparation of the tables. In addition, MK, HM, AA, MAM, KC, OGK, RG, AJ, JL, EO, JV, FO, SM, AR, ISO and IYA played an important role in drafting the recommendations, revising the manuscript, approving the final version, and agreeing to be accountable for all aspects of the work to ensure that any issues related to accuracy or integrity are properly investigated and resolved.
Corresponding author
Correspondence to Michelle Kenyon.
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Kenyon, M., Onida, F., Assanelli, A. et al. The role of palliative and supportive care in haematopoietic cell transplantation and cellular therapy. Recommendations from the EBMT practice harmonisation and guidelines committee. Bone Marrow Transplant (2026). https://doi.org/10.1038/s41409-026-03061-2
Received: 29 July 2026
Revised: 12 September 2026
Accepted: 21 September 2026
Published: 26 October 2026
Version of record: 26 October 2026
DOI: https://doi.org/10.1038/s41409-026-03061-2
来源:Nature 健康护理主题 · nature.com